| 1 |
30186977 | Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. | 2018 Aug |
1 |
| 2 |
24466173 | Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. | 2014 |
1 |
| 3 |
22285846 | Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. | 2012 Mar |
2 |
| 4 |
20501849 | Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. | 2010 Jun 15 |
2 |
| 5 |
18199598 | Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. | 2008 Jul |
1 |
| 6 |
17956583 | Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. | 2007 Dec |
1 |